How much of the effect is delayed gastric emptying versus central satiety?

This matters because it predicts what a related molecule should do.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Why does this happen, and what would falsify the usual explanation?

The short version: glucose-dependent insulinotropic action, glucagon suppression, delayed gastric emptying and central appetite effects, from one receptor in four places.

Native GLP-1 has a circulating half-life of one to two minutes because dipeptidyl peptidase-4 cleaves the two N-terminal residues. Substituting the position-8 alanine, as the long-acting analogues do, blocks that cleavage and is the single most consequential modification in the class.

Glucose-dependence arises because the insulinotropic signal amplifies glucose-stimulated secretion rather than initiating secretion. With no glucose signal to amplify, there is little to amplify.

Area postrema involvement in nausea from this class is supported by lesion studies in animals and by the anatomy of the circumventricular organs.

Research-use material is not approved for human use, and mechanism is not a safety argument.

Nausea and appetite share an anatomy, which is why they are hard to separate by dose.

On the detail: the glucose-dependence is the key property. Below about four millimoles per litre the insulinotropic effect largely disappears, which is why monotherapy hypoglycaemia is uncommon.

Albumin binding does the rest of the work. A fatty-acid chain attached through a linker binds circulating albumin reversibly, which both shields the peptide from renal clearance and creates a depot; that is how a two-minute hormone becomes a once-weekly drug.

Mechanically, gastric emptying delay attenuates with continued exposure for long-acting agents through receptor desensitisation, which is why the early nausea usually settles while the appetite effect persists.

The position-8 substitution conferring DPP-4 resistance appears in essentially every long-acting agent in the class, which is about as strong a piece of convergent evidence as medicinal chemistry offers.

The half-life problem and the albumin-binding solution are the whole story of the class chemically.

Answer first: the receptor is a class B G-protein-coupled receptor signalling mainly through Gs and cyclic AMP, and almost every downstream effect people ask about traces back to where that receptor is expressed rather than to what it does when activated.

Biased agonism — differential recruitment of beta-arrestin versus G-protein signalling — is an active research area and is one hypothesis for why agents with similar receptor affinity have different tolerability.

The incretin effect itself was established by comparing the insulin response to oral and intravenous glucose loads matched for plasma glucose; the difference is what the gut hormones contribute.

The caveat is that mechanism predicts direction and rarely predicts magnitude in an individual, and people reason from mechanism to dose far too confidently.

Tissue distribution first, then signalling. Nearly every question in this tag resolves at the first step.

Start with the tissue distribution. Pancreatic islet, gastric, and several hypothalamic and brainstem populations — that list explains insulin secretion, gastric emptying and appetite in one go.

Receptor density and downstream coupling differ between tissues, so the dose-response curves for glycaemia, weight and nausea are not the same curve. That is the pharmacological basis for titration.

The structural basis of semaglutide’s pharmacokinetics — Aib-8, the Arg34Lys substitution and the C18 diacid–AEEA linker at Lys26 — is described in the original medicinal chemistry publication, and it is worth reading once because it makes the design logic explicit[1].

Nothing here is medical advice; this is pharmacology.

Glucose-dependence is the property to remember; it explains the safety profile on its own.